

SUBJECT INDEX TO VOLUME 6

<p>Abnormal pregnancies551</p> <p style="padding-left: 20px;">factor XII (hageman factor) in552</p> <p style="padding-left: 20px;">high molecular weight kinogen in.....554</p> <p style="padding-left: 20px;">prekallikrein in553</p> <p style="padding-left: 20px;">role of factor XIII.....551</p> <p style="padding-left: 20px;">role of kinogen551</p> <p style="padding-left: 20px;">role of plasma prekallikrein551</p> <p>Acute lymphoblastic leukaemia.....639</p> <p style="padding-left: 20px;">apoptosis regulation in640</p> <p style="padding-left: 20px;">cell-specific drug delivery in.....641</p> <p style="padding-left: 20px;">cyclin-dependent kinases (Cdks) signaling in.....640</p> <p style="padding-left: 20px;">JAK/STAT signaling in.....640</p> <p style="padding-left: 20px;">membrane proteins as therapeutic targets in641</p> <p style="padding-left: 20px;">modulation of intracellular signaling in641</p> <p style="padding-left: 20px;">proteasomal regulation in.....641</p> <p style="padding-left: 20px;">protein kinase signaling in639</p> <p style="padding-left: 20px;">RAS signaling in640</p> <p style="padding-left: 20px;">regulating gene transcription by histone</p> <p style="padding-left: 40px;">acetylation/deacetylation in.....639</p> <p style="padding-left: 20px;">vinca-alkaloids in639</p> <p style="padding-left: 20px;">intercellular signaling systems as therapeutic targets in639</p> <p>Acute myelogenous leukaemia (AML).....631</p> <p style="padding-left: 20px;">anthracyclines in.....637</p> <p style="padding-left: 20px;">apoptosis regulation in640</p> <p style="padding-left: 20px;">cell-specific drug delivery in.....641</p> <p style="padding-left: 20px;">cyclin-dependent kinases (Cdks) signaling in.....640</p> <p style="padding-left: 20px;">elucidation of conventional chemotherapy</p> <p style="padding-left: 40px;">mechanisms for637</p> <p style="padding-left: 20px;">future perspectives of.....643</p> <p style="padding-left: 20px;">intercellular signaling systems as therapeutic targets in.....639</p> <p style="padding-left: 20px;">JAK/STAT signaling in.....640</p> <p style="padding-left: 20px;">membrane proteins as therapeutic targets in641</p> <p style="padding-left: 20px;">methodological strategies for631</p> <p style="padding-left: 20px;">modulation of intracellular signaling in641</p> <p style="padding-left: 20px;">p53-p73 pathway in.....642</p> <p style="padding-left: 20px;">proteasomal regulation in.....641</p> <p style="padding-left: 20px;">protein kinase signaling in639</p> <p style="padding-left: 20px;">proteomic methodologies for633</p> <p style="padding-left: 20px;">proteomics in631</p> <p style="padding-left: 20px;">RAS signaling in640</p> <p style="padding-left: 20px;">regulating gene transcription by histone</p> <p style="padding-left: 40px;">acetylation/deacetylation in.....639</p> <p style="padding-left: 20px;">searching for novel drug targets of.....642</p> <p>Acute pain797</p> <p style="padding-left: 20px;">relief of.....797</p> <p>Acute promyelocytic leukaemia638</p> <p style="padding-left: 20px;">apoptosis regulation in640</p> <p style="padding-left: 20px;">cell-specific drug delivery in.....641</p> <p style="padding-left: 20px;">cyclin-dependent kinases (Cdks) signaling in.....640</p> <p style="padding-left: 20px;">differentiation induction in.....638</p> <p style="padding-left: 20px;">intercellular signaling systems as therapeutic targets in639</p> <p style="padding-left: 20px;">JAK/STAT signaling in.....640</p> <p style="padding-left: 20px;">membrane proteins as therapeutic targets in641</p>	<p>modulation of intracellular signaling in 641</p> <p>proteasomal regulation in 641</p> <p>protein kinase signaling in..... 639</p> <p>RAS signaling in 640</p> <p>regulating gene transcription by histone</p> <p style="padding-left: 20px;">acetylation/deacetylation in..... 639</p> <p>Adipokines 525</p> <p style="padding-left: 20px;">as therapeutic targets for metabolic syndrome 525</p> <p>Adiponectin..... 526</p> <p>Adipose derived stem cells (ASC)57</p> <p style="padding-left: 20px;">differentiation of58</p> <p style="padding-left: 20px;">for therapies in neural diseases/injuries 61</p> <p style="padding-left: 20px;">function of.....59</p> <p style="padding-left: 20px;">in transdifferentiation.....60</p> <p style="padding-left: 20px;"><i>in vitro</i> modeling using59</p> <p style="padding-left: 20px;"><i>in vivo</i> modeling using.....60</p> <p style="padding-left: 20px;">into non-neural lineages.....58</p> <p style="padding-left: 20px;">neuronal differentiation of58</p> <p style="padding-left: 20px;">therapeutic potential of57</p> <p>Adipose tissue58</p> <p style="padding-left: 20px;">as alternative source of stem cells.....58</p> <p>Adiposity hormone.....155</p> <p style="padding-left: 20px;">acute blockade of157</p> <p style="padding-left: 20px;">effect on food intake and/or energy expenditure ...157</p> <p style="padding-left: 20px;">effect on neuronal activity in brain centers.....156</p> <p style="padding-left: 20px;">exogenous administration of.....156</p> <p style="padding-left: 20px;">to regulate body weight.....156</p> <p>α_2-Adrenergic receptors749</p> <p style="padding-left: 20px;">anatomic location of.....749</p> <p style="padding-left: 20px;">classification of.....749</p> <p style="padding-left: 20px;">molecular pharmacology of.....750</p> <p>α_2-Adrenergic receptor agonists750</p> <p style="padding-left: 20px;">clonidine as750</p> <p style="padding-left: 20px;">dexmedetomidine as.....750</p> <p style="padding-left: 20px;">mivazerol as.....750</p> <p style="padding-left: 20px;">physiological actions of.....750</p> <p>Adult human NSCS97</p> <p style="padding-left: 20px;">amplification of.....98</p> <p style="padding-left: 20px;">differentiation of98</p> <p style="padding-left: 20px;">expansion of.....97</p> <p style="padding-left: 20px;">large-scale expansion of.....100</p> <p style="padding-left: 20px;">source of.....97</p> <p style="padding-left: 20px;">tracking <i>in vivo</i>.....100</p> <p>Adult neural stem cell therapy97</p> <p style="padding-left: 20px;"><i>in vitro</i>.....97</p> <p style="padding-left: 20px;"><i>in vivo</i>.....97</p> <p style="padding-left: 20px;">in clinical transplantation.....97</p> <p>Adult stem cell63</p> <p style="padding-left: 20px;">application of63</p> <p style="padding-left: 20px;">delivery of exogenous66</p> <p style="padding-left: 20px;">future research of71</p> <p style="padding-left: 20px;">in spinal cord injury63,66,70</p> <p style="padding-left: 20px;"><i>in vivo</i> mechanisms of.....70</p> <p style="padding-left: 20px;">research in human spinal cord injury71</p>
--	--

Advanced glycation end products (AGEs)	447,453	in diabetic microvascular complications	475
breakers of	449	in retinal pericyte lost	478
effect of benfotiamine	449	in vascular permeability	478
effect of amadorins	449	mediated pathologies in non-vascular cells.....	479
effect of antihypertensive drugs	449	Aldose reductase (polyol) pathway	487
effect of anti-inflammatory drugs	449	Allylamines	900
effect of synthetic AGE inhibitors	449	mechanisms of resistance of	902
exposure to exogenous	467	spectrum of antifungal activity of	902
in cardiac function.....	458	Alpha-2 agonists.....	749
in diabetic cardiovascular disease	453	in postanesthesia care unit.....	749
in macrovascular disease.....	455	Aminoglycosides.....	353
induce microvascular injuries	448	development of suicide inhibitors of.....	358
inhibition of accumulation of.....	460	enzymatic inactivation of	355
inhibitors of formation of.....	449	targeting binding pocket of.....	358
interactions of.....	448	Aminoglycoside acetyltransferases (AACS).....	356
novel inhibitors of formation of.....	468	Aminoglycoside phosphotransferases (APHS).....	355
receptor-dependent actions of	456	Aminoglycoside resistance.....	353
receptor-independent effects of.....	455	active drug extrusion in	354
role of antioxidant compounds.....	449	antisense strategy to.....	359
soluble ligands for.....	467	design of novel inhibitors for	353
synergy with pathogenic pathways	459	exploiting bridged binding site in.....	359
targeting of	449	molecular mechanisms of.....	354
trapping of	449	molecular targets for.....	353
Advanced glycation end product formation (AGE).....	488	prevention of drug entry in.....	354
Afibrinogenemia	536	strategies for design modifying enzyme	
in pregnancy	536	inhibitors of	357
murine model of	537	targeting nucleotide binding pocket in	359
paradoxical thrombosis in	537	Aminoglycoside nucleotidyltransferases (ANTS)	357
role of FG-/-mice.....	537	AMP-PKA signaling pathway.....	655
supplemental therapy for.....	537	adenylyl cyclases in.....	655
AGE inhibitors	453	components of	655
alpha-lipoic acid as.....	469	cyclic AMP dependent protein kinase (PKA)	656
aminoguanidine as.....	460	cyclic AMP receptors in.....	656
antioxidants as.....	469	cyclic AMP-regulated guanidine exchanging	
blockade of RAS by	469	factors in.....	656
carnosine as	468	cyclic nucleotide gated ion channels in.....	656
in diabetic cardiovascular disease	453	phosphodiesterases in.....	656
LR compounds as	469	Amyotrophic lateral sclerosis (ALS)	407
OPB-9195 as	466	clinical features of	407
oral hypoglycemics as	469	epidemiology of.....	408
pyridoxamine as	463	genetics of.....	408
thiamine as	462	histopathology of.....	408
transition metal chelators as.....	469	Analgesics	774
vitamin B derivatives as	463	devices for nasal administration of.....	774
AGE-RAGE interactions	450	Analgesia.....	767
blocking of	450	clinical application of	769
role of endogenous secretory RAGE (esRAGE).....	451	fentanyl in.....	769
role of neutralizing RAGE antibody	451	in PACU	767
role of soluble RAGE (sRAGE).....	450	intravenous opioids in	767
AGE-RAGE system	447	morphine in.....	767
blockade of diabetic vascular injury by	447	receptors in	767
Alagebrium chloride	465	remifentanyl in	769
Aldose reductase	475	sufentanyl in	769
AR/albuminuria in.....	480	Angiogenesis	518,667
AR/extracellular matrix accumulation in.....	480	angiogenic factors in	667
ARI clinical studies of.....	481	perlecan in	667
clinical studies of.....	479		

Antiangiogenic factors.....	668	platelets activation in.....	598
betaglycan as.....	668	oxidant-mediated vascular endothelium lesions in.....	598
collagen XVIII/endostatin as.....	668	possibilities of prothrombotic effects in.....	598
endorepellin as.....	668	upregulation of tissue factor in.....	598
Antibodies.....	926	inhibition of protein C pathway in.....	598
to fungal sphingolipids.....	926	reduction of fibrinolytic activity.....	598
Antifungal.....	929	interference with phospholipid binding proteins	
clinical relevance of susceptibility test results of.....	929	regulating hemostasis in.....	599
development of standardized methods for.....	930	clinical features in pregnancy.....	599
rationale for susceptibility testing of.....	929	pthogenetic mechanisms of obstetric	
susceptibility testing methods for.....	929	complications in.....	599
Antifungal drug discovery.....	924	treatment of.....	600
fungal sphingolipids as targets for.....	924	management of.....	600
Antifungal drug targets.....	909	Antipsychotics.....	811
mutagenesis strategies to.....	918	Antisense oligonucleotides.....	21
RNA interference as target in.....	917	clinical trials in neurological disease.....	24
Antifungal susceptibility testing.....	934	delivery to CNS.....	23
agar-based methods for.....	937	design of.....	22
breakpoint testing in.....	937	for treatment of neurological diseases.....	21
developments in.....	934	perspectives of.....	27
new test development for.....	934	specificity of.....	22
progress in.....	934	synthesis of.....	22
use of flow cytometry.....	938	technology of.....	21
use of spectrophotometry.....	934	Antithrombin (AT).....	559
Antiglutamatergic agents.....	607	acquired deficiency of.....	560
as mood-stabilizers.....	607	hereditary deficiency of.....	560
gabapentin as.....	612	in fetal loss.....	563
in bipolar disorder.....	607	in thromboembolism.....	560
lamotrigine as.....	609	physiology of.....	559
oxcarbazepine as.....	611	pregnancy-induced deficiency of.....	562
rationale for use of.....	608	role in preeclampsia.....	562
role of.....	607	treatment of preeclampsia with concentrates of.....	562
sodium valproate as.....	612	Antithrombin abnormalities.....	559
topiramate as.....	610	antithrombin concentrates in.....	561
zonisamide as.....	610	choice of anticoagulant in.....	561
Antimycotic treatment.....	859	hepains in.....	561
future concerns for.....	859	perinatal management of.....	559
Antimycotics.....	853,860,887,895	thromboprophylaxis in.....	561
mode of action of.....	895	Antithrombin deficient mice.....	560
resistance occurrence of.....	895	Antithrombotic therapy.....	692
skin kinetics of.....	853	Apolipoprotein AIV.....	145
spectrum of.....	895	as satiety factor.....	147
Antiphospholipid syndrome.....	593	central action of.....	148
characteristics of.....	593	effect of peptide YY.....	146
obstetrical management of.....	593	hormonal regulation of endogenous.....	145
role of antiphospholipid antibodies (APLS).....	593	in cerebrospinal fluid (CSF) of third	
role of anti beta2-GPI antibody.....	594	cerebroventricle.....	147
role of anti-prothrombin antibody (aPT).....	595	in control of food intake.....	145
role of other aPL antibodies.....	595	in fasting.....	146
origin of autoimmunity in.....	595	in lipid refeeding.....	146
laboratory tests of.....	596	intracerebroventricular hypothalamic.....	148
use of ELISA.....	596	lipid absorption of.....	145
use of lupus anticoagulant (LA).....	596	on upper gastrointestinal function.....	149
prolongation of PL-dependent clotting time in.....	596	role in body weight regulation.....	150
clinical implications of.....	597	role in obesity.....	150
thrombogenic characteristics/mechanisms of.....	597	role of leptin.....	145
activation of endothelial cells in.....	597		

synthesis by GUT	145	angiogenic factor perlecan in therapy of	675
synthesis by hypothalamus	146	antiangiogenic factor endostatin in therapy of	675
<i>Aspergillus fumigatus</i>	876	changes in proteoglycan expression/structure in	668
biology of	876	collagen XVIII/endostatin in	669
genetics of	876	glypican/syndecan in therapy of	675
iron acquisition in	881	glypicans in	670
role of palyketide synthase	882	HA/HYAL in therapy of	676
Aspergillus infection	877	heparanase in	672
process of	877	heparanase inhibition in	676
response of immune system in	877	heparitinase in	673
Astrocytes	430	hyaluronidase in	673
role of NCAMS	430	metastatic process in	666
Atopic dermatitis	859	MMP in	673
Atypical neuroleptics	812	matrix as barrier in	666
Axial regeneration promoting factor	377	proteoglycan degradation in	671
approaches to discovery of	377	receptor CD44 in	671
Azoles	902	role of matrix in development of	666
alteration of membrane sterol composition by	905	sulfation in	669
alterations in target enzyme of	905	syndecan in	669
development of resistance of	905	targeting heparan sulfate proteoglycans in	665
mechanism of antifungal action of	902	Cancer therapy	325
mechanism of resistance of	903	aurora kinases in	327
overproduction of target enzyme of	905	BMS-387032 in	331
reduced intracellular accumulation of	904	Bub1/Bub1/Mps1 in	329
spectrum of antifungal activity of	903	cell cycle kinases in	325
Benzodiazepines	745,812	cell cycle regulation of Cdks in	327
and other sedatives	747	checkpoint kinase proteins Chk1/Chk2 in	329
in ICU	746	cyclin-dependent kinases in	327
pharmacology of	745	E7070 in	330
role of	745	first generation Cdk inhibitors in	329
Blood/urine markers	674	flavopiridol in	329
HA as	674	Hsp 90 inhibition in	332
HYAK as	674	indirect cell cycle kinase inhibitors in	332
Bone	701	Nek kinases in	329
biology of	701	non-Cdk cell cycles kinase in	327
remodeling of	701	non-Cdk cell cycle kinase inhibitors in	332
Bone marrow mesenchymal stem cells	31	pharmacologic inhibitors of	329
integral therapeutic potential of	31	polo-like kinases in	328
Bone marrow progenitor cells	34	proteasome inhibition in	332
for endogenous tissue repair	34	R-roscovitine in	331
Brain	427	second generation cell cycle kinase inhibitors in	330
glycan-binding proteins in	427	targeting ATP-binding pocket in	326
protein glycosylation in	427	targeting other sites in	326
Brain DA/NE systems	192	UCN-01 in	330
carcadian studies of	193	<i>Candida</i> infections	863
effects of indirect agonists of	194	adaptation host	868
effects on feeding	194	analysis virulence attributes of	869
Brain disorders	89	epidemiology of	863
Brain injury	104	from commensalisms to dissemination of	864
clinical transplantation for	104	identification of	869
Cancers	665	interaction with blood components	868
and angiogenesis	667	interaction with macrophages	868
		molecular approaches for	869
		process of	864
		virulence attributes of	869
		with host cells within target organs	867
		Cannabinoid receptors	215

Catecholamine.....	194	echinocandins in.....	853
contribution of.....	196	griseofulvin in.....	850
microinjections into brain	194	morpholine derivatives in.....	853
to amphetamine-induced hypophagia	196	polyenes in.....	850
CB ₁ receptor antagonists.....	218	Dermatophytes	859
clinical studies with.....	218	Des-acyl ghrelin	160
Cell cycle kinases.....	325	effect on insulin secretion.....	161
Cell transplantation	8	physiologic function of.....	160
for demyelinating diseases.....	8	Developing/adult CNS	4
mechanisms of action of.....	10	lineage-restricted progenitors in	4
migration of transplanted cells in brain	9	stem cells in	4
noninvasive methods for tracking.....	12	Diabetes.....	496,503
problematic issues in	8	effect on oxidative stress in.....	496
route of cell delivery in.....	9	mechanism for oxidative stress in.....	496
Central reward mechanisms.....	217	PKC-dependent activation of NAD(P)H	
and cannabinoid receptor ligands.....	217	oxidase in.....	496
Chronic pain.....	797	role of angiotensin II on oxidative stress in	497
relief of.....	797	Diabetic cardiovascular complications	487
CNS derived stem/progenitor cell.....	111	altered expression of cytokines in	491
endogenous	111	molecular targets of.....	487
exogenous	111	treatment of.....	492
for neurotrauma	111	vascular inflammation in	190
in brain.....	113	vasomotor mediators in	492
in spinal cord	113	Diabetic complications.....	475
Colloidal carriers.....	363	activation of PKC in.....	477
for ophthalmic drug delivery.....	363	effect on NO synthesis	477
physiological considerations of.....	363	role of non-enzymatic glycation.....	476
Colloidal carriers systems	366	role of oxidative stress.....	477
role of liposomes	368	role of pseudohypoxia	476
role of microemulsions.....	369	Diabetic nephropathy	479,481
role of nanoparticles.....	366	animal models for.....	479,482
role of niosomes	369	AR /glomerular hyperfiltration in.....	480
Congenital afibrinogenemia.....	535	AR expression in neural tissues.....	482
in humans	535	ARI clinical studies in	483
Congenital blood coagulation factor XIII deficiency	541	ARI intervention studies in.....	480,482
genetic abnormalities identified in.....	545	ARI prevention studies of.....	479,482
management of pregnancy/delivery in.....	547	ARI-mediated vascular metabolic dysfunction in ...	483
perinatal management of.....	541	transgenic models of.....	480
recurrent fetal loss and	547	transgenic/gene knockout mice studies in.....	482
role in maintaining pregnancy.....	547	Diabetic retinopathy	477,511
Cutaneous fungal infections.....	860	AR expression in retinal cells in.....	478
preventive measures for	860	ARI intervention studies in.....	478
DA receptors	195	ARI prevention studies in.....	478
in feeding.....	195	basement membrane thickening in	478
DAG-PKC pathway	489	experimental models for.....	477
activation of.....	489	medical approaches for.....	517
Demyelinating disorders	3	role of neurotoxicity	513
animal models for	3	role of oxidative stress.....	511
Dermatophyte skin infections	849	therapeutic strategies for blocking VEGF	
origin of.....	849	pathological effects in	517
Dermatology	850	therapies for	517
allylamines in	853	use modifiers of proteolysis	518
antimycotic drug classes in	850	use of cannabinoids	519
azoles in.....	850	use of corticosteroids.....	520
		use of cyclooxygenase-2 inhibitors	520
		use of growth hormone.....	520
		use of HMG CoA reductase inhibitors	519

use of pigment epithelial derived factor (PEDF)	519	mutations of.....	260
vascular endothelial growth factor in.....	511	selection of monoclonal antibodies targeting.....	275
VEG role in.....	514	Epidermal growth factor-induced survival pathways	289
Diabetic vascular complications	495,503	ABX-EGF as	295
ACE-inhibitors for	506	antitumor therapeutic strategies based on	289
antioxidant therapy in.....	504	as therapeutic targets	292,296
ATI receptor antagonists for	506	cetuximab/erbitux® as	295
3-hydroxy-3-methylglutaryl coenzyme A		erlotinib/tarceva® as	295
reductase inhibitors in	504	gefitinib/iressa® as.....	295
calcium channel blockers for	507	regulators of.....	289
molecular targets of.....	503	targeting of	289
role of PKC activation in.....	495	Epidural analgesia	795
therapeutic approach for.....	504	efficacy of.....	797
thiazolidinediones for.....	507	in post-anesthesia care unit.....	795
Diaper dermatitis.....	859	ErbB receptors.....	243
DNAzymes.....	647	as transforming genes <i>in vitro/in vivo</i>	249
and Ras-RaF signaling pathway.....	650	dimerization of	244
as therapeutics	647	diversification of signaling network of	246
in target validation.....	649	expressed in human carcinoma.....	247
protein kinase C as.....	651	from family of tyrosine kinase receptors.....	244
Dopamine (DA)	191	in cancer	243
Drug delivery devices	85	intracellular signaling pathways of.....	245
formulation of	85	ligands of	243
nature of polymer of	85	role in development.....	246
Dual ERBB receptor inhibitors.....	269	transactivation by other signaling pathways	245
Eating	191	Erlotinib.....	266
circadian studies of	193	in other tumors.....	267
effect of catecholamines.....	193	in NSCLC.....	266
effect of central catecholamine systems	191	in combination with chemotherapy	267
NE/DA receptor subtype agonists of.....	195	preclinical data of	266
modulation of.....	191	pharmacodynamic/pharmacokinetics studies of....	266
Echinocandins	897	Eye	363
mechanism of antifungal action of.....	897	anatomy of posterior segment of.....	363
mechanisms of resistance of.....	898	new drug delivery systems in	365
spectrum of antifungal activity of	898	topical drug delivery into	363
EGF-like peptide.....	252	Factor V leiden.....	567
in oncogenic transformation.....	252	adverse pregnancy outcome by	569
EGFR	290	association of mutation with adverse pregnancy	
activating mutations/prioritization of.....	294	outcome	568
biological significance targeting of.....	292	effect on outcome of pregnancy	567
induced antiapoptotic survival pathways	290	hereditary thrombophilia in newborn infants with.	573
overexpression of	293	in abruption.....	570
prioritization of.....	293	in maternal health.....	567
EGFR-TK inhibitors	261	in maternal venous thromboembolism	568
gefitinib as.....	261	in pre-eclampsia	569
EGFR-TK inhibitor activity.....	259	intrauterine growth restriction.....	570
small molecules with.....	259	late pregnancy loss by	569
EKB-569	269	management of adverse pregnancy outcome	
Endogenous 5-HT	202	in women with.....	572
in altered nutritional status.....	203	recurrent fetal loss by	569
synthesis of.....	202	role of	567
Energy homeostasis	158	screening in pregnant women.....	573
Epidermal growth factor receptor (EGFR, HER1)	275,259	Factor XIII (FXIII).....	541
mechanisms of activation/signaling pathways of...	259	functional properties of	543
		function of	544

role in maintaining pregnancy.....	547	research on.....	909
structural properties of	541	target identification of	910
Farnesyl transferase inhibitors	313	Fungal sphingolipids	923
clinical development of	313	targets for development of selective antifungal	
Farnesylpyrophosphate synthase inhibitors	310	therapeutics.....	923
Fibrinogen disorders	535	Fungicidal activity.....	938
classification of	535	determination of	938
Filamentous fungi	932		
standardized broth dilution methods for	932	Galactin-1	375,395,407,419,427,437
Fluorinated pyrimidines	896	as component of neurofilamentous lesions	
mechanism of antifungal action of.....	896	in sporadic/familial ALS	409
mechanism of resistance of	896	as downstream target of FOSB.....	440
spectrum of antifungal activity of	896	as executor of biological functions of FOSB	441
FosB	437	as novel factor	395
as transcription factor.....	437	as therapeutic agent	407
biological functions of.....	439	associated with skin change in ALS.....	414
inducible expression in brain	438	biological roles of.....	380
regulation of neuronal fate by	437	enhancement of BDNF production in astrocytes	
Fungal biofilms	887	by galectin-1	432
factors contributing to drug resistance in.....	890	experssion of.....	419
<i>in vitro</i> susceptibility of	888	expression in adult primary sensory neurons	420
<i>in vivo</i> susceptibility of	890	expression patterns/function in regenerating	
methods to study antifungal susceptibility of.....	887	intramuscular nerves.....	401
resistance against antifungal agents of.....	888	expression patterns/function in regenerating	
role of drug efflux pumps.....	892	myofibers.....	399
role of slowed/drug penetration	892	expression pattern in motoneuron development	
role of candida filamentation	893	/adulthood.....	422
role of extracellular matrix.....	891	expression pattern in sensory neuron development	419
role of physiological state	890	for amyotrophic lateral sclerosis	407
role of sterol composition.....	893	functional studies of	375
Fungal diagnostic tests	946	functions of.....	419
using nuclear medicine techniques.....	946	glycans in.....	427
Fungal genome sequencing projects	910	in transgenic mouse model of ALS	414
Fungal infections.....	849,945	in adult dorsal root ganglion neurons	420
antimycotic therapy in.....	849	in inflammatory responses.....	396
combination therapy in.....	859	in motoneurons	422
detection of.....	945	in myofiber necrosis	396
diagnostic tests of	945	in primary sensory neuron development	419
efficacy of antifungal therapy in	952	in regenerating skeletal muscles.....	395
antimicrobial peptides in.....	947	in sensory/motoneurons.....	419
of skin.....	849	in skeletal muscle regeneration	396
process of	849	in skeletal muscle	399
radiolabeling of peptides in.....	950	induced expression of neurotrophic factors	
role of antimicrobial peptides	950	in astrocytes.....	427
role of radiolabeled antifungal agents.....	945	ligands of	431
scintigraphic detection with 99m Tc-antimicrobial		neuroprotective effect of	414
peptides	949	novel axonal regeneration-promoting activity of... 375	
scintigraphic detection with 99mTc-fluconzole.....	947	redox-regulated dimerization of	441
treatment of	946	regulates myotube growth	395
Fungal pathogens	909	regulation of myoblast fusion.....	397
effect of macrophages	913	role in neuropathic pain.....	422
effect of neutrophils	915	role in regenerative response of injured DRG	
in blood.....	915	neurons	421
mutagenesis in.....	917	role in regenerative response of injured	
novel/molecular approaches for	909	motoneurons	423
protemic approach to.....	916	role in sensory neuron development.....	419
		structural studies of	375
		Galectin family.....	375

Gefitinib	261	Histone deacetylase	337
in combination with chemotherapy	264	targeting of	342
in NSCLC	262	Host-pathogen interactions	911
in other tumors	265	animal models of	911
pharmacodynamic studies of	262	biofilm model of	913
pharmacokinetics of	262	host immune response of	913
safety of	262	<i>in vivo</i> transcript profiling in	913
Ghrelin	153	mammalian models of	911
as saginary survival hormone	163	non-mammalian models of	912
biochemistry of	153	Hsp90 client proteins	339
current controversies for	153	Hsp90 inhibitors	341
effect on food intake	159	as anti-tumor agents	341
effect on gastrointestinal (GI) motility	162	5-HT receptors	202
expression of	153	in food intake	203
in brain	158	animal studies of	203
in energy balance	153	5-HT receptor knockouts	204
model of	163	in food intake	204
receptor agonists of	162	in obesity	204
receptor for	153,160	5-HT satiety system	202
roles in long-term body-weight regulation	155	interaction with other neuropeptide signaling	
roles in meal initiation	154	pathways	202
to treat wasting conditions	162	Huntington's disease (HD)	43
Glycosylation	429	apoptosis in	46
in diseases	429	cell replacement in	47
Griseofulvin	895	cell therapy of	43,47
mechanism of antifungal action of	896	excitotoxicity in	45
mechanism of resistance of	896	<i>in vivo</i> drug delivery for	50
spectrum of antifungal activity of	896	metabolic toxicity in	46
Growth factors	68	molecular therapy of	43,45
genetic modification for over expression of	68	new frontiers for	43
HDAC inhibitors	344	role of neural stem cells	48
as anti-tumor agents	344	stem cells transplantation in	48
Heat shock protein 90	337	therapies of	45
inhibitors of	337	transcriptional dysregulation in	46
multiple-target drugs	337	transglutaminase in	46
targeting of	338	Hyperglycemin	503
Hematological neoplasias	683	Hypothalamic Apo AIV	148
angiogenesis in	683,685	diurnal rhythm of	148
anti-angiogenesis as therapeutic target in	686	ICU	746
hemostasis in	683	diazepam in	746
interference with angiogenic receptors to treat	689	flumazenil in	746
interference with angiogenic stimulators to treat	688	lorazepam in	746
interference with extracellular matrix (ECM)		midazolam in	746
to treat	690	Ingestive behaviour	215
interference with proteolysis to treat	690	regulation of	215
Hematopoiesis	642	role of cannabinoids	215
Hemostasis	683	role of CB ₁ receptor antagonists	218
and cancer	683	role of endocannabinoids	215
angiogenic factors in	684	role of exogenous cannabinoid receptor ligands	216
as therapeutic target	692	role of peripheral CB ₁ receptors in	217
control of	687	Injury	113
hematological malignancy and	693	as stimulus	113
regulation of coagulation in	693	Integrins	398
role of TF	693	Interleukin-6 (IL-6)	525
role of TFPI	693		

Intracellular proteins	301	in physiological healing	34
as target for therapy of human neoplasms.....	301	in skeletal muscle.....	36
isoprenylation of.....	301	in spinal cord injury	37
preclinical/clinical implications of.....	301	<i>in vitro</i> differentiation of.....	33
strategies for the inhibition of prenylation in.....	306	isolation of	32
Intracranial hypertension	732	potential participation of.....	34
control of.....	732	site specific differentiation of.....	35
Isoprenylation inhibition.....	311	surface markers of.....	32
strategies for potentiation of.....	311	systemically delivered migration of.....	35
		therapeutic benefits of.....	35
		unresolved issues of.....	38
Kallikrein-kininogen-kinin system	552	Metabolic regulators.....	218
in pregnancy	552	Monoclonal antibodies	275
Ketamine.....	789	and chemotherapeutic drugs.....	280
cardiovascular effects of	791	and radiation therapy.....	279
clinical use of	792	and targeted agents	283
during regional/local anesthesia.....	793	targeting epidermal growth factor receptor.....	275
for major abdominal surgery.....	792	Multiple myeloma	701
in intra/perioperative analgesia	792	additional targets for bone resection inhibition in..	708
in post-anaesthesia care.....	793	effect of osteoprotegerin (OPG).....	705
neurological effects of.....	790	effect of receptor activator of NF- B (RANKL) ...	705
pain therapy with.....	793	mediators of.....	705
pharmacology of.....	789	osteoblast differentiation/function in.....	702
pulmonary effects of	791	osteoblast stimulating agents in.....	708
		osteoclast differentiation/function in.....	703
		principal aspects of.....	701
		role of RANKL inhibition	707
		therapeutic options in	706
		use of bisphosphonates.....	706
99mTc-labeled peptides	950	Multiple sclerosis (MS).....	3
imaging of <i>Aspergillus fumigatus</i> infections in		current treatments of	3
immunocompromised mice using.....	951	myelin regeneration in	4
imaging of <i>Candida albicans</i> infections in		rationale for cell transplantation in	5
mice using	950	remyelination fails in	5
Lachrymal systems.....	363	role of myelin repair in	5
anatomy of.....	363	transplantation of myelin-forming cells in.....	5
Laminin.....	398	Muscle satellite cells.....	397
Leptin	526	Myelodysplastic syndromes (MDS).....	713
		angiogenesis in	718
Mabs anti-EGFR	276	apoptosis in.....	716
activity of	276	chromosome aberration in	713
in angiogenesis.....	278	classification of.....	713
in apoptosis.....	277	clinical features of	714
Maternal fibrinogen	535	disease mechanisms of	715
for embryonic development	535	DNA hypermethylation in	719
M-cadherin.....	398	DNA mutations in	717
M-calpain	398	epigenetic modulation in	721
Mesenchymal stem cells (MSC)	31,58	erythroid differentiation in	718
clinical trials of.....	38	erythroblast cultures of.....	717
culture of.....	32	estimation of prognosis of.....	714
definition of	32	farnesyl transferase inhibitors in	721
expansion of.....	32	gene expression profiling in	719
history of.....	32	hematopoietic growth factors in	720
in brain injury	36	histone deacetylation in.....	719
in central nervous system	36	immune-modulation in	720
in expression of homing related receptors.....	34	immunosuppressive treatment of.....	720
in infected heart	36	ineffective hematopoiesis in.....	716
in neurodegenerative disease.....	37		
in peripheral blood.....	34		
in peripheral nerve injury	38		

mechanisms of apoptosis in	716	phosphoinositide 3-kinase in	303
microenvironment in	718	post-translational maturation in	304
mitochondrial ferritin in	717	Rac/Rho in	303
mitochondrial morphology in	717	Raf-1 in	303
oncogenes in	719	serine-threonine kinase MEKK1 in	303
paradox of	719	statins in	318
process of apoptosis in	715	target prioritization of	311
role of mitochondria	715	Nervous system	429
strategies for biology/molecular-based treatment of	713	astrocyte glycans in	430
T-cell-mediated bone marrow failure in	718	lectins in	429
therapeutic approaches directed towards TNF- /		Nestin	822
angiogenesis/microenvironment in	720	as marker	822
treatment of	719	Nestin-expressing reactive astrocytes	822
Myelin diseases	3	in basal ganglia on MPTP-PD model	822
animal models of	3	Neural stem cell	66,119,121
rationale for cell transplantation in	5	viability of	118
role of myelin repair in	5	on artificial scaffolds for implantation	121
stem cell therapy for	3	Neural stem cell transplantation	118
timing of	8	considerations for	118
transplantation of myelin-forming cells in	5	experimental/clinical studies of	119
Myelin-forming cells	6	for SCI	119
bone marrow stromal cells (BMSCs) as	8	for TBI	119
embryonic stem (ES) cells as	7	into CNS	118
neural stem cells as	6	regional specification of cell fate of	120
olfactory nerve-ensheathing cells (OECs) as	6	Neurogenesis	114,830
oligodendrocyte lineage as	6	environmental effects on	114
remyelination by	6	in adult brains	830
schwann cells as	6	Neurological diseases	21
Myocardial ischaemia	732	antisense strategies in	21
protection against	732	perspectives of	27
NAD(P)H oxidase	495	Neurological disorders	81
activation in adipocytes/metabolic syndrome	498	combining cell graft/drug delivery systems in	86
activation of	495	growth factor delivery from microparticles in	86
as target for preventing diabetic vascular		growth factor releasing polymeric devices in	84
complications	498	growth factors delivery in	84
as potential target mechanism for diabetic vascular		polymeric drug delivery devices in	85
complications	495	polymeric scaffolds in	89
for preventing beta cell dysfunction	498	role of embryonic stem cells	83
for preventing metabolic syndrome	498	role of somatic stem cells	83
in metabolic syndrome	495	stem cell therapy in	57,82
in pancreatic -cells	497	surface modified scaffolds in	88
in progressive -cell dysfunction	495,497	therapeutic approach for	81
molecular mechanism for high glucose-induced		treatment of	81
activation of NAD	497	use of polymeric devices	81
NE receptors	195	use of stem cells	81
in feeding	195	Neuronal cell adhesion molecule (NCAM)	398
Neoplasms	301	Neuronal disorders	90
farnesyltransferase in	304,307	combining stem cells/polymeric devices for	90
geranyl-geranyltransferase inhibitors in	307	future therapy for	90
geranyl-geranyltransferases in	304	Neurons	100
HMG CoA inhibitors in	306	functional integration of	100
intracellular targets of RAS in	303	survival of	100
mevalonate pathways in	304	Neuropathic pain	75
multi-step enzyme inhibition in	311	animal models of	76
other drugs targeting Ras signaling pathways in	318	classical treatment of	76
other small Ras-related G proteins in	302	gene therapy in	77

role of gene therapy	75	role of serotonin (5HT)	234
stem cell therapy in	78	use of 5-HT receptor agonists	208
treatment of	76	use of 5-hydroxytryptophan (5-HT)	205
viral vector therapy in	78	use of d-fenfluramine	205,208
Neuropeptide Y (NPY)	146,202	use of fenfluramine	205
and increased energy intake	203	use of fluoxetine	206
and reduced energy intake/body weight	203	use of selective 5-HT receptor agonists	207
central administration of	146	use of sibutramine	206
role in control of food intake/energy balance	202	use SSRIs	208
Non-proteinaceous antifungal agents	946	Oncogenes	290
Nonsteroidal anti-inflammatory drugs	781	computational system biology for	297
analgesic efficacy of	782	RNA interference for	296
clinical use of	785	prioritization/activation in targeting of SPS	295
in cardiovascular system	784	technologies of molecular profiling for	296
in gastrointestinal	783	Onychomycoses	856
in postoperative bleeding	784	Ophthalmic delivery	363
opioid sparing effect of	783	physiological considerations of	363
other side effects of	785	role of liposomes	368
renal effects of	783	role of microemulsions	369
side effects of	783	role of nanoparticles	366
Norepinephrine (NE)	191	role of niosomes	369
circadian studies of	193	Opioids	767,773
effects of indirect agonists of on feeding	194	adverse effects with fentanyl patches of	776
Novel antileukaemic therapy	631	clinical use in postoperative pain	778
identification of protein targets for	631	in chronic pain therapy with	776
intercellular signaling systems as therapeutic		iontophoresis system of	776
targets in	639	nasal administration of	773
proteomic methodologies for	633	pharmacodynamic studies of	778
regulating gene transcription by histone		pharmacology of	767
acetylation/deacetylation in	639	pharmacokinetic of	778
role of mass spectrometry	635	receptors in	768
role of protein arrays	637	-receptors in	768
role of protein separation	633	transdermal delivery systems in PACU	777
Nuclease-resistant ribozymes	647	use in recovery room	773
Obesity	201,225	Oral transmucosal opioids administration (OTMF)	778
brain signals affecting regulation of		Osteolytic bone disease	701
metabolism in	230	additional targets for bone reseption inhibition in ..	708
drugs for	210	in multiple myeloma	701
peripheral signals affecting regulation of		osteoblast differentiation/function in	702
metabolism in	226	osteoblast-inhibiting factors in	706
regulation of energy balance in	225	osteoblast stimulating agents in	708
role of Agouti related protein (AGRP)	230	role of RANKL inhibition	707
role of cholecystokinin	229	targets for therapy of	701
role of ciliary neurotrophic factor (CNTF)	235	therapeutic options in	706
role of cocaine/amphetamine regulated transcript		use of bisphosphonates	706
(CART)	231	Oxidative stress	503
role of ghrelin	229	Oxidized galectin-1	385
role of glucagon-like peptide 1 (GLP-1)	233	as essential factor for peripheral nerve	385
role of hypothalamus	225	expression in adult RAT peripheral nerves	386
role of insulin	228	externalization from neurons/schwann cells	386
role of leptin	226	in acellular allograft models	387
role of melanin concentrating hormone (MCH)	231	in axonal regeneration after peripheral nerve	
role of melanocortins	230	injury	387
role of neuropeptide Y (NPY)	230	in freeze/crush model of mouse sciatic nerve	387
role of orexine/hypocretins	234	in frozen/thawed acellular autograft	387
role of peptide YY (PYY ₃₋₃₆)	230	in nerve-transection plus tublization model	387
		macrophages as target cell of	290

promotes functional recovery in peripheral nerves after freeze/transect axotomy.....	390	adverse effects of.....	816
role in initiation of axonal growth after axotomy ...	388	choice of opioid in.....	815
stimulates macrophages to release factor essential for axonal regeneration.....	291	devices of.....	815
stimulates macrophages to release factor	290	effectiveness of.....	816
to promotes axonal regeneration following peripheral nerve injury	290	limitation of	818
		management of	815
		organization issues of	816
		setting of	815
		vs. regional analgesia.....	817
		vs. conventional opioid analgesia.....	816
PACU.....	741,745,755	Phenacylthiazolium bromide (PTB).....	465
analgesia in.....	755	Phenothiazinium based photosensitizers	615
complications of.....	755,761	administration of.....	616
guidelines of.....	763	and bacteria as target organisms.....	621
indications of.....	755,757	and other microbes as target organisms	624
monitoring of.....	755,759	and viruses as target organisms	623
role of propofol	741	as PACT agents	621
sedation in	745	as PDT agents.....	617
Pain	755	as photodynamic agents	615
of deep/visceral part.....	756	cellular targets of.....	615
of incisional.....	756	clinical application as antibacterial agents	621
of localized muscle spasm.....	756	clinical application as anti-tumour agents	619
of positioning	756	clinical application as antiviral agents.....	623
pathophysiology of.....	755	clinical applications of.....	615
Pancreatic amylin.....	181	light delivery of	616
anorectic effect beyond AP.....	184,185	mechanisms of anti-tumour action of.....	617
as centrally acting satiating hormone	181	photochemistry of.....	616
as physiological satiating agents.....	181	photodynamic action of.....	616
central pathways for.....	185	sites of antibacterial action of.....	621
effect on feeding	181	sites of antiviral action of	623
effect on gastric function	186	Pityriasis versicolor	857
hypothalamic involvement in anorectic action of..	185	Plant/insect defensins	925
in body weight regulation	186	Plasminogen activator inhibitor-1 (PAI-1).....	525
in longer term regulation of food intake.....	186	Polyenes	899
pathophysiological/clinical aspects of.....	186	mechanism of antifungal action of	899
prandial drinking by.....	184	mechanism of resistance of	900
site of action of	184	spectrum of antifungal activity of	900
PAN-ERBB receptor inhibitors	271	Polymeric scaffold properties	88
Parkinson' disease (PD).....	821	Polyol pathway.....	475
as targets in novel cell replacement therapy	821	and osmotic stress.....	476
Peptide YY.....	171	expression of enzymes in kidney.....	479
as therapy for obesity.....	171	mechanisms of induced diabetic lesions by	476
biological actions of.....	173	Post anesthesia anesthesia care unit (PACU)729,749, 773,781,795	
factors regulating release of.....	172	agitation by	802
from L cells of gut	172	analgesia in.....	781
gastric surgery.....	177	anxiety in	750
identification of.....	171	assessment of.....	796
orexigenic/anorexigenic effects of.....	174	cardiovascular complications of.....	801
processing of.....	171	complications encountered in.....	750
receptor specificity of	172	complications of	729,800
studies in obese rodent models	176	confusion by	802
tertiary structure of	172	delirium in	752
tissue distribution of	172	drowsiness by	802
Percutaneous transdermal fentanyl (PCTF).....	775	efficacy of analgesia in.....	796
Perioperative analgesia	757	pidural failure in	797
Patient-controlled analgesia (PCA).....	815	hemodynamic instability in	752
adjuvant drugs for	816		

in airway management	731	physiological role in anticoagulation system	585
in mechanical ventilation	731	variant of.....	586
indications of.....	729	Protein C	577
length of stay in.....	803	natural properties of.....	577
monitoring of.....	733,729	mechanisms of action of.....	577
nasal opioids for pain control in.....	773	Protein C-deficiency	577
nausea in.....	752	in early abortion.....	580
neurological assessment of.....	753	in preeclampsia.....	582
pain in	750	in pregnancy loss.....	578
postoperative nausea by	800	mechanisms of action of.....	577
postoperative shivering by	803	natural properties of.....	577
respiratory complications in.....	751,800	pregnancy management in patients with.....	577
sedation in	729	role of antiphospholipid antibodies	582
shivering in.....	750	Protein kinase A (PKA)	655
side effects of	800	as therapeutic target for treatment of	
vomiting by	752,800	immunodysfuntion.....	661
Postoperative delirium	807	in dysfunctional immune cells.....	655
assessment of.....	808	in regulation of immune function.....	658
causes of.....	809	in T cell activation.....	658
clinical presentation of.....	807	role in HIV.....	661
course of.....	808	role in SLE.....	661
environmental interventions of	809	subcellular localization A by AKAPs	658
incidence of	808	target for therapeutic intervention	655
pharmacological management of	810	targets activity of molecules involved in T	
predisposing factors of	809	cell activation	659
prevention of	809	Protein S/congenital protein S deficiency	585
pathogenesis of.....	809	congenital thrombophilia in Japanese by	585
therapy of	809	factors affecting serum level of.....	587
Precursor cells	5	frequency of.....	586
in adult CNS	5	gene mutation of.....	586
regenerating oligodendrocytes by.....	5	management during pregnancy/puerperium.....	588
requesting myelin by	5	management/treatment for.....	588
Pregnancy	567,587	obstetric complications with.....	588
physiological changes in coagulation system		risk of occurrence of venous thromboembolism	586
during	567	types of hereditary	586
VTE with PS deficiency in.....	587	Proteoglycan	674
Prenylation inhibitors	313	as tumor marker in blood/urine	674
BMS-214662 in.....	316	PYY3-36	176
L-778, 123 in.....	317	effects on food intake in humans	176
SCH 66336.....	313	effects of peripheral infusion of.....	176
R115777 in.....	314	RAS	301
Propofol	741	function of	301
chemical properties of.....	741	structure of.....	301
complications of use of	743	RAS-related small G proteins	301
effect on cardiovascular	742	function of	301
effect on central nervous system	742	Reactive astrocytes	821
effect on respiratory	742	anti-oxidant functions of	827
effects on organ systems	742	as micro-environmental dominator in basal	
other effects of.....	743	ganglia of PD.....	822
pharmacodynamics of	741	as neural progenitor cells in.....	829
pharmacokinetics of	741	as source of neurotrophins/cytokines	824
role of propofol	741	as targets in novel cell replacement therapy.....	821
vs. midazolam for ICU sedation.....	744	characterization of	822
Propylene glycol	747	for neurogenesis in adult brains	829
use of	747	in anti-glutamate excitotoxicity.....	827
Protein	585		
physiological character of	585		

in basal ganglia of PD animal models.....	822	effects on appetite expression.....	201
in modulation of microglial cells	827	effects on food intake in rodents	203
in prevention of oxidative stress injuries	827	in obesity	208
neuroprotective role of trophic factors		rodent studies of	208
released from.....	826	use for treatment of obesity.....	201
neurotrophins expressed in.....	824	use of fenfluramine.....	208
pharmacological intervention of	830	Serotonin NPY	202
Receptor for AGE (RAGE).....	447	and melanocortin system.....	202
interactions of.....	448	and orexin.....	202
inhibitors of signaling of.....	451	animal studies of.....	204
targeting of	449	in feeding behaviour.....	204
Renal cell carcinoma (RCC).....	835	role in control of food intake/energy balance.....	202
apoptosis in.....	838	Small interfering RNAs.....	21,647
combination targeting in	842	and cytokines	651
down-stream signaling pathways in	837	and Ras-Raf signaling pathway	650
fargeting angiogenesis in.....	838	as therapeutics.....	647
future clinical trial design in	842	delivery to CNS	23
PI3/Akt pathway of	841	design of.....	23
Raf/MEK/ERK in.....	838	for treatment of neurological diseases	21
Raf/MEK/ERK signaling of.....	840	in neurological diseases	26
targeted agents for.....	835	in target validation	649
targetin ubiquitin-proteasome pathway.....	841	perspectives of	27
targeting down-stream signaling pathways of.....	840	and protein kinase C	651
targeting EGF.....	840	specificity of	23
targeting G250 antigen.....	841	synthesis of	23
targeting ligands/receptors of.....	838	technology of	22
targeting VEGF.....	838	Sphingolipids.....	925
treatment of	835	antifungal compounds interacting with.....	925
tumor cell proliferation in	838	Spinal cord injury (SCI).....	63,89,111
VHL pathway of.....	836	clinical trials of	120
Resistin.....	526	current status of.....	112
Ribozymes.....	647	cytoplasmic labels for	117
and Ras-RaF signaling pathway.....	650	early development of cell therapy for	65
as therapeutics	647	labeling/identifying transplanted neural stem	
in target validation.....	649	cells for	116
protein kinase C	651	membrane labels for.....	117
Satiating factor	182	molecular events in	63
interaction with metabolites.....	183	neural stem cell transplants for	116
role of endogenous amylin as	182	neurotrophic/growth factors in.....	114
relationship with CCK/BBS	182	non-CNS derived stem cells for.....	120
Scaffold systems	88	nuclear labels for.....	116
polymeric devices as.....	88	regenerative failure in	63
Schwann cell migration.....	389	role of reporter genes	118
rh GAL-1/Ox stimulates by.....	389	stimulating endogenous neural stem cell	
Sciatic nerve injury	391	response in	113
mechanism underlying initiation of axonal		treatment in humans.....	112
regeneration after	391	Stem cells	57,68
Scintigraphy	950	of non-neural origin	68
9mmTc-labeled antimicrobial peptides for	950	sources of	57
Seborrheic dermatitis	857	Superficial skin infections.....	855
Sedation.....	741	treatment of.....	855
Serotonin (5-HT) drugs.....	201	Syngomycin E.....	925
and weight loss.....	208	Systemic fungal infections	863,875
clinical data of.....	208	adhesion factors in.....	869
effect on feeding behaviour in humans	205	by <i>Aspergillus</i> species	875
		by <i>Candida</i> species.....	863
		cAMP signaling in.....	883

enzyme based anti-oxidant activity in.....	882	neural stem cell transplants for	116
epidemiology of	863,875	neurotrophic/growth factors in.....	114
infection process of	863,875	non-CNS derived stem cells for.....	120
morphogenesis in	870	nuclear labels for.....	116
phenotypic switching in	871	role of reporter genes	118
proteases in.....	882	stimulating endogenous neural stem cell	
protein toxins in.....	882	response in	113
putative secondary metabolites in	881	treatment in humans.....	112
secondary metabolites in.....	881	Tumor cell proliferation	837
secreted hydrolases in	870	effects on HIF-inducible factors on.....	837
target organs of <i>Candida albicans</i> during.....	867	Tumor markers	674
virulence attributes in.....	863,869	endostatin as	674
virulence determinants of.....	875,880	glypican as.....	674
		sydecan as.....	674
Thiocarbamates	900	Tumor necrosis factor (TNFa).....	525
mechanism of antifungal action of.....	900		
mechanisms of resistance of.....	902	Vascular oxidative stress.....	488
spectrum of antifungal activity of	902	VEGF	514
<i>Tinea barbica</i>	856	in cell survival	516
<i>Tinea corporis</i>	856	in novascularization.....	514
<i>Tinea faciei</i>	856	in vascular permeability	514
<i>Tinea manus</i>	856	indirect modulators of	518
<i>Tinea pedis</i>	856	inhibitors of expression of.....	518
<i>Tinea capitis</i>	855	regulation expression of	516
Transplanted cells	118	VEGF receptors.....	514
intrinsic markers of.....	118	Venous thrombotic disease	692
Traumatic brain injury (TBI)	111	association with cancer.....	692
clinical trials of	120	Visfatin.....	527
current status of	112		
cytoplasmic labels for.....	117	Yeasts	930
labeling/identifying transplanted neural stem		standardized broth dilution methods for.....	930
cells for	116	standardized disk diffusion methods for	930
membrane labels for	117		